xamoterol has been researched along with sumatriptan in 6 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (sumatriptan) | Trials (sumatriptan) | Recent Studies (post-2010) (sumatriptan) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 2,405 | 461 | 480 |
| Protein | Taxonomy | xamoterol (IC50) | sumatriptan (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.4497 | |
| Carboxypeptidase M | Homo sapiens (human) | 0.02 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.722 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.3091 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 0.0131 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 7.9433 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.9753 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.804 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.061 | |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | 5.5 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.0078 | |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | 0.5012 | |
| 5-hydroxytryptamine receptor 1D | Sus scrofa (pig) | 0.02 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.45 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 0.0073 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 6.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Blomgren, A; Börjesson, L; Gustavsson, L; Hendrickx, R; Jenvert, RM; Johansson, JG; Lohmann, C | 1 |
6 other study(ies) available for xamoterol and sumatriptan
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
Topics: Biological Transport; Chemical Phenomena; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Pharmaceutical Preparations; Reproducibility of Results; Structure-Activity Relationship; Substrate Specificity | 2013 |